S. 4440, Clinical Trial Equity & Accessibility Reform. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 4440 · Net good
What it does
This bill modernizes clinical trials by making it easier to recruit and retain participants from underrepresented populations—including racial minorities, rural communities, and low-income groups.
The analysis names pharmaceutical companies (faster enrollment, reduced attrition, diverse trial data) — and 3 more groups — among the beneficiaries.
The trade-off
Pharmaceutical and device companies gain significant operational benefit (faster enrollment, reduced attrition, more diverse trial cohorts) while the public bears the cost of equity through tax expenditures and anti-kickback carve-outs that reduce enforcement leverage.
Transparency scores 65%, with a medium warning level and no detached riders.
Who is behind it
Filed by Tim Scott. Cosponsored by Mark Warner.